JP2013507926A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507926A5
JP2013507926A5 JP2012534364A JP2012534364A JP2013507926A5 JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5 JP 2012534364 A JP2012534364 A JP 2012534364A JP 2012534364 A JP2012534364 A JP 2012534364A JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5
Authority
JP
Japan
Prior art keywords
binding agent
bispecific binding
linker moiety
igf
erbb3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012534364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507926A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052712 external-priority patent/WO2011047180A1/en
Publication of JP2013507926A publication Critical patent/JP2013507926A/ja
Publication of JP2013507926A5 publication Critical patent/JP2013507926A5/ja
Pending legal-status Critical Current

Links

JP2012534364A 2009-10-14 2010-10-14 IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用 Pending JP2013507926A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25142609P 2009-10-14 2009-10-14
US61/251,426 2009-10-14
PCT/US2010/052712 WO2011047180A1 (en) 2009-10-14 2010-10-14 Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof

Publications (2)

Publication Number Publication Date
JP2013507926A JP2013507926A (ja) 2013-03-07
JP2013507926A5 true JP2013507926A5 (cg-RX-API-DMAC10.html) 2013-11-21

Family

ID=43511327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534364A Pending JP2013507926A (ja) 2009-10-14 2010-10-14 IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用

Country Status (6)

Country Link
US (2) US20120244163A1 (cg-RX-API-DMAC10.html)
EP (1) EP2488199A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013507926A (cg-RX-API-DMAC10.html)
AU (1) AU2010306774A1 (cg-RX-API-DMAC10.html)
CA (1) CA2777242A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011047180A1 (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US20140134170A1 (en) * 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX336197B (es) * 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
IN2014CN03887A (cg-RX-API-DMAC10.html) * 2011-10-27 2015-10-16 Genmab As
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
CA2855864A1 (en) 2011-11-17 2013-05-23 Gundram Jung Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
KR101814370B1 (ko) * 2011-12-27 2018-01-12 재단법인 생물기술개발중심 경쇄-가교된 이중특이성 항체
CN104684579A (zh) * 2012-04-02 2015-06-03 梅里麦克制药股份有限公司 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
IN2015DN01115A (cg-RX-API-DMAC10.html) 2012-07-13 2015-06-26 Zymeworks Inc
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
EP2920210B1 (en) * 2012-11-19 2017-08-30 Baliopharm AG Recombinant bispecific antibody binding to cd20 and cd95
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015130554A2 (en) * 2014-02-20 2015-09-03 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US20180169230A1 (en) 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
EP3432936A1 (en) * 2016-03-24 2019-01-30 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
US10723857B1 (en) * 2016-04-15 2020-07-28 United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration Polyimide aerogels with reduced shrinkage from isothermal aging
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
CN109400711B (zh) * 2017-05-31 2022-02-08 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CA3095582A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗her3抗体-薬物コンジュゲート投与によるher3変異がんの治療
EP3897849A1 (en) * 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
KR20230156921A (ko) * 2021-03-12 2023-11-15 젠맵 에이/에스 비-활성화 항체 변이체
JPWO2024248123A1 (cg-RX-API-DMAC10.html) 2023-06-02 2024-12-05

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP4355571B2 (ja) 2001-07-19 2009-11-04 ウニベルジテート チューリッヒ ヒト可変ドメインの改変
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
KR20090014471A (ko) 2007-08-06 2009-02-11 삼성전자주식회사 잉크젯 화상형성장치
JP5639039B2 (ja) * 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
MX336197B (es) * 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.

Similar Documents

Publication Publication Date Title
Gandullo-Sánchez et al. HER3 in cancer: from the bench to the bedside
US20250127858A1 (en) Novel cytokine prodrugs
US10428149B2 (en) Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
BR112021005907A2 (pt) citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
WO2021062406A1 (en) Cytokine prodrugs and dual-prodrugs
JP2020501531A5 (cg-RX-API-DMAC10.html)
JP2016520586A5 (cg-RX-API-DMAC10.html)
CN108463245A (zh) 具有修饰的j链的结合分子
RS62151B1 (sr) Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
JP7097293B2 (ja) ヒトFc受容体に結合する融合タンパク質
JP7752132B2 (ja) Her2を標的とする抗原結合構築物及び用途
JP2020503860A (ja) 免疫応答のコンディショナルアゴニスト
JP2018501211A5 (cg-RX-API-DMAC10.html)
WO2020068774A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
WO2023049909A1 (en) Composition of recombinant antigen binding molecules and method of making and using thereof
WO2021110990A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
WO2024193705A1 (en) Tnf superfamily member immunocytokine and uses thereof
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
CN103172741B (zh) 全人源抗egfr抗体
Bakherad et al. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity
WO2022214664A1 (en) Improved interferon-gamma mutant
CN118139884A (zh) 人源化抗clec-1a抗体和其抗原结合片段及其模拟物
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
RU2844389C2 (ru) Her2-нацеленные антигенсвязывающие конструкции и их использование
WO2012024659A2 (en) Antibody-based constructs directed against tyrosine kinase receptors